|
|
Article: Bernhard Hampl, Ph.D. Elected to Serve as Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc.
- Article from:
- Business Wire
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SCHAUMBURG, Ill. -- Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ), which acquired APP Pharmaceuticals, Inc., September 10, 2008, today announced the election of Bernhard Hampl, Ph.D. to its Board of Directors effective November 1, 2009. Dr. Hampl, also named as Executive Chairman of the Board, succeeds current Chairman Dr. Ulf M. Schneider. Dr. Schneider will continue to serve on the Board of Directors and as a member of the Audit Committee.
"Dr. Hampl is one of the most experienced and well-respected leaders in the generic pharmaceutical industry. His addition to the Board both strengthens and broadens the depth of our industry expertise," said ...